Integrated BioPharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Integrated BioPharma generated cash of $943,000, which is less than the previous year. Cash used in financing activities reached the amount of -$29,000 last year. Net change in cash is therefore $361,000.
Cash Flow
| 2015 | -113K | -156K | -111K |
|---|---|---|---|
| 2016 | -594K | -107K | 1.02M |
| 2017 | 397K | -327K | -333K |
| 2018 | 1.16M | -242K | -830K |
| 2019 | 328K | -422K | 341K |
| 2020 | 1.33M | -110K | -1.30M |
| 2021 | 3.05M | -199K | -3.04M |
| 2022 | 4.09M | -465K | -3.50M |
| 2023 | 1.23M | -111K | -136K |
| 2024 | 943K | -553K | -29K |
INBP Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.31M | 331K | 210K | 402K | 475K | 228K | 132K | 395K | 71K | 451K |
Operating activities | ||||||||||
Net income | 112K | -34K | 3.83M | 8.01M | 4.10M | 1.68M | 679K | 2.34M | 958K | 735K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.22M | 1.15M | 834K | 826K | 772K | 774K | 348K | 393K | 351K | 405K |
Stock-based compensation expense | 252K | 320K | 369K | 231K | 59K | 144K | 0 | 49K | 31K | 104K |
| Deferred income tax benefit | 252K | 320K | 369K | 231K | 59K | 144K | 0 | 49K | 31K | 104K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -120K | 374K | 927K | -294K | -1.08M | -593K | 182K | -884K | -527K | -440K |
Inventories | -983K | 794K | 640K | -1.59M | -1.28M | -1.07M | -96K | 111K | -1.97M | -79K |
Accounts payable | 244K | -921K | -218K | -937K | 487K | -329K | 7K | -1.29M | 727K | -488K |
Cash generated by operating activities | 943K | 1.23M | 4.09M | 3.05M | 1.33M | 328K | 1.16M | 397K | -594K | -113K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | -4K | 0 | -192K | 0 | -8K | -1K | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -553K | -116K | -486K | -295K | -214K | -414K | -247K | -327K | -109K | -235K |
Acquisitions Net | 0 | 4K | 21K | 96K | 101K | -8K | -1K | 0 | 2K | 79K |
Cash generated by investing activities | -553K | -111K | -465K | -199K | -110K | -422K | -242K | -327K | -107K | -156K |
Financing activities | ||||||||||
Common Stock Issued | 13K | 4K | 34K | 96K | 101K | 24K | 0 | 3K | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -42K | -136K | -3.53M | -60.72M | -50.16M | 84K | -42.13M | -802K | -42.15M | -111K |
Cash used in financing activities | -29K | -136K | -3.50M | -3.04M | -1.30M | 341K | -830K | -333K | 1.02M | -111K |
Net Change In Cash | 361K | 985K | 121K | -192K | -73K | 247K | 96K | -263K | 324K | -380K |
Cash at end of period | 1.67M | 1.31M | 331K | 210K | 402K | 475K | 228K | 132K | 395K | 71K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |